Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
21.81
+0.41 (1.92%)
At close: Dec 5, 2025, 4:00 PM EST
22.24
+0.43 (1.97%)
After-hours: Dec 5, 2025, 6:16 PM EST
Enliven Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Enliven Therapeutics stock have an average target of 41.2, with a low estimate of 27 and a high estimate of 52. The average target predicts an increase of 88.90% from the current stock price of 21.81.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jul 2, 2025.
Analyst Ratings
The average analyst rating for Enliven Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $48 | Strong Buy | Maintains | $40 → $48 | +120.08% | Jul 2, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $37 | Strong Buy | Initiates | $37 | +69.65% | Jun 16, 2025 |
| Baird | Baird | Buy Maintains $40 → $52 | Buy | Maintains | $40 → $52 | +138.42% | Jun 16, 2025 |
| Jones Trading | Jones Trading | Strong Buy Maintains $36 → $27 | Strong Buy | Maintains | $36 → $27 | +23.80% | May 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $39 → $40 | Strong Buy | Maintains | $39 → $40 | +83.40% | May 15, 2025 |
Financial Forecast
Revenue This Year
8.50K
Revenue Next Year
8.50K
from 8.50K
EPS This Year
-1.76
from -1.89
EPS Next Year
-2.00
from -1.76
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 52,500 | 52,500 | ||||
| Avg | 8,497 | 8,497 | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 517.9% | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.73 | -1.63 | ||||
| Avg | -1.76 | -2.00 | ||||
| Low | -1.76 | -2.34 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.